Aldeyra Therapeutics, Inc.

What they do

Aldeyra discovers and develops pharmaceuticals that modulate protein systems rather than inhibiting or activating single targets. Its product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246 and chemically related molecules, plus late-stage candidates reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191, an intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa. The company has no approved products and no product revenue.

Revenue drivers

• Reproxalap U.S. collaboration (potential) — If AbbVie exercises its option and the parties enter the Collaboration Agreement, AbbVie would pay a $100.0 million upfront cash payment less the $1.0 million option payment and $5.0 million extension fee, with U.S. profits and losses split 60% to AbbVie and 40% to Aldeyra.
• Reproxalap ex-U.S. royalties (potential) — Outside the United States, Aldeyra would be eligible for tiered royalties on net sales of reproxalap under the Collaboration Agreement.
• Regulatory and commercial milestones (potential) — Aldeyra would be eligible for up to approximately $300.0 million in regulatory and commercial milestone payments, including a $100.0 million milestone payable upon the FDA Decision regardless of whether the Collaboration Agreement is executed before or after that decision.
• Option and extension fees received to date — AbbVie has paid a non-refundable $1.0 million option payment and a $5.0 million extension fee; both would be credited against the upfront cash payment if the Collaboration Agreement is entered into.

Recent performance

Aldeyra reported net losses of $57.8 million (2021), $62.0 million (2022), $37.5 million (2023), $55.9 million (2024) and $33.8 million (2025), with diluted EPS of $-1.07, $-1.06, $-0.64, $-0.94 and $-0.56 respectively. Operating cash flow was negative in each year: $-42.6 million, $-56.6 million, $-30.3 million, $-43.2 million and $-33.3 million. As of June 30, 2026, total assets were $47.5 million, total liabilities $9.7 million, shareholder equity $37.9 million and cash and equivalents $45.1 million. Long-term debt was $0.00 as of March 31, 2026. The company recorded no product revenue in the periods covered by the provided filings.

Strategy

The stated approach is to develop pharmaceuticals that modulate protein systems to affect multiple pathways while limiting toxicity. Near-term priority is resolving the FDA's issues with the reproxalap NDA for dry eye disease, where the FDA has issued Complete Response Letters. Aldeyra has agreed under the November 2024 Expansion Side Letter to conduct launch activities costing no more than mid-single-digit millions of dollars without AbbVie's approval, with 60% of allowable expenses reimbursable by AbbVie only if AbbVie exercises its option and the Collaboration Agreement is executed. AbbVie has also independently begun pre-commercialization planning. Aldeyra continues development of RASP modulators ADX-248 and ADX-246 and ADX-2191.

Risks

• Reproxalap approval risk — Success depends on addressing the issues raised by the FDA in the reproxalap Complete Response Letters; failure or delay would significantly delay any revenue.
• AbbVie option not exercised — As of February 27, 2026, AbbVie has not exercised its option, and if it declines, Aldeyra remains solely responsible for launch activity costs already undertaken and would need alternative funding or a partner.
• Funding requirement — The company has had negative operating cash flow every year from 2021 to 2025 and may be unable to raise additional capital to fund further development and commercialization of reproxalap if it remains responsible for those costs.
• Pipeline concentration — The business is dependent in large part on successful commercialization of reproxalap, and other candidates such as ADX-248, ADX-246 and ADX-2191 are earlier-stage.

Outlook

Management states that development plans and timelines are subject to adjustment based on recruitment rate, regulatory review, preclinical and clinical results, funding and other factors. The company flags the likelihood and timing of a potential reproxalap NDA resubmission and of AbbVie's option exercise as key uncertainties. No revenue guidance or profitability timeline is provided in the excerpts.